Crescent Biopharma (NASDAQ:CBIO) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Crescent Biopharma (NASDAQ:CBIO) from a sell rating to a hold rating in a report published on Sunday.

Several other brokerages also recently commented on CBIO. HC Wainwright restated a “buy” rating and set a $25.00 price objective on shares of Crescent Biopharma in a research report on Wednesday, August 27th. Jefferies Financial Group assumed coverage on shares of Crescent Biopharma in a report on Monday, August 25th. They issued a “buy” rating and a $26.00 target price for the company. Finally, Weiss Ratings initiated coverage on Crescent Biopharma in a report on Wednesday, November 12th. They set a “sell (e-)” rating on the stock. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $25.60.

Crescent Biopharma Price Performance

NASDAQ CBIO opened at $13.00 on Friday. Crescent Biopharma has a 52 week low of $9.81 and a 52 week high of $42.20. The company has a market capitalization of $180.61 million, a P/E ratio of -0.37 and a beta of 1.50. The stock has a 50-day moving average of $12.43.

Crescent Biopharma (NASDAQ:CBIO) last released its earnings results on Thursday, November 6th. The biopharmaceutical company reported ($1.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.01) by ($0.26). On average, analysts forecast that Crescent Biopharma will post -0.16 EPS for the current fiscal year.

Hedge Funds Weigh In On Crescent Biopharma

Several institutional investors have recently bought and sold shares of the business. Bank of America Corp DE purchased a new stake in Crescent Biopharma during the second quarter valued at approximately $149,000. Citadel Advisors LLC bought a new position in shares of Crescent Biopharma during the 3rd quarter valued at approximately $304,000. Two Sigma Investments LP purchased a new stake in Crescent Biopharma during the 3rd quarter valued at $337,000. Jefferies Financial Group Inc. purchased a new stake in Crescent Biopharma during the 2nd quarter valued at $437,000. Finally, Adage Capital Partners GP L.L.C. bought a new stake in Crescent Biopharma in the second quarter worth $1,629,000. Institutional investors own 75.19% of the company’s stock.

Crescent Biopharma Company Profile

Crescent Biopharma, Inc operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.